Abstract
Purpose: To investigate the prognostic value of bright edge sign observed on high b-value diffusion-weighted imaging (DWI) map in glioma patients.Methods: We retrospectively reviewed our prospectively collected database for gliomas. Bright edge sign was defined as the presence of extremely high signal in tumor margin on high b-value DWI map (b = 3,000 s/mm2) with the signal intensity higher than those in contralateral normal white matter and tumor central region. Extremely poor prognosis was defined as overall survival time < 9 months. Survival analyses were conducted by using the Cox regression for both the univariable and multivariable analyses.Results: A total of 52 patients were enrolled (WHO IV, 25; WHO III, 13; WHO II, 14). Bright edge sign presented in 10 (19.2%) patients (WHO IV, 5; WHO III, 3; WHO II, 2). Nine (90.0%) patients with bright edge sign had extremely poor prognosis, while only 1 (2.4 %) patient without bright edge sign had extremely poor prognosis. The sensitivity and specificity of bright edge sign in determining extremely poor prognosis were 90 and 97.7%, respectively. Bright edge sign (HR [95% CI] = 25.11 [7.26–86.81], p < 0.001) was an independent predictor of poor prognosis after adjustment.Conclusion: Bright edge sign on high b-value DWI may be an accurate predictor of extremely poor prognosis in glioma patients, regardless of pathologic grades.
Highlights
Glioma is the most common malignant tumor in the brain, accounting for about 80% of all primary malignant tumor [1]
Bright edge sign was defined as the presence of extremely high signal in tumor margin on high b-value diffusion-weighted imaging (DWI) map (b = 3,000 s/mm2) with the signal intensity higher than those in contralateral normal white matter and tumor central region
Bright edge sign (HR [95% CI] = 25.11 [7.26–86.81], p < 0.001) was an independent predictor of poor prognosis after adjustment
Summary
Glioma is the most common malignant tumor in the brain, accounting for about 80% of all primary malignant tumor [1]. Treatment for gliomas has been evolved, some patients still had very poor prognosis. Glioblastoma (GBM) is the most common type of gliomas with a median survival time of about 15 months. Some patients with lower grade gliomas (LGG) (WHO grade II and III) have a poor prognosis. Predicting the prognosis of patients is critical for neurosurgeons to make individualized treatment plan.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
